Ferroptosis

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Friday, April 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

Journal of Pharmaceutical Analysis (JPA) Studies Find Promising Drug Candidates

Retrieved on: 
Friday, March 29, 2024
Hydralazine, Issue 1, DHT, Pigment, UBA52, Neuroregeneration, Prevalence, Apoptosis, PNI, Serum, Homeostasis, Patient, Ferroptosis, JPA, Neuron, HYD, Metformin, Type, Nerve, BPH, Hypopigmentation, EB, Depigmentation, Met, Oxidative stress, Iron, Pharmaceutical industry

XI'AN, China, March 29, 2024 /PRNewswire/ -- Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action.

Key Points: 
  • The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH).
  • The article was published in Volume 14, Issue 1 of the journal in January 2024 .
  • Using the Drug Signatures Database, they identified hydralazine (HYD), a potent arterial vasodilator, as a potential UBA52 disruptor.
  • Further studies will hopefully clarify the intricate connections among cellular processes, diseases, and potential drugs, paving the way for precise and efficient therapies.

Harvey J. Berger, M.D. Joins Kojin Therapeutics as Chairman, President, and Chief Executive Officer

Retrieved on: 
Wednesday, January 3, 2024
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Ferroptosis, Immunology, Cameron Boyce, Broad Institute, Drug discovery, Autoimmune disease, Science, Virology, Janssen Pharmaceuticals, Research, Chemical biology, MIT, Dana–Farber Cancer Institute, Apoptosis, Conditional sentence, Yale School of Medicine, Bayer, Yang, Therapy, Cancer, Investment, Polaris Partners, ARIAD Pharmaceuticals, Medicine, Harvard University, Yale New Haven Hospital, Scripps Research, Patient, Cardiovascular disease, Colgate University, Harvard Medical School, Organization, Yale school, Wolf Prize, Pharmaceutical industry

Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.

Key Points: 
  • Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.
  • as its new chairman, president, and chief executive officer.
  • He founded ARIAD Pharmaceuticals and led the company from a start-up to a fully integrated global oncology company.
  • Kojin co-founder Professor Stuart Schreiber stated, “We are thrilled to welcome Dr. Berger, a long-time colleague and collaborator, as Kojin’s new chief executive.

Wistar Scientists Identify Esophageal Cancer Biomarkers

Retrieved on: 
Wednesday, December 6, 2023
RNA, Wistar Institute, Ferroptosis, Collaborative writing, RNA-Seq, National Cancer Institute, Biomedical Research, Culture, Mechanics, Tumor microenvironment, Ellen, Virus, ESCA, Messenger, Prognosis, Health, Ageing, Incidence, Neoplasm, Cancer, International Society, University, University of Pennsylvania, Ecology, Gene expression, Gene, Biomarker, Machine learning, Cell, Patient, Qi, Iron, NCI, Bacteriophage, Esophageal cancer, Carnegie Mellon University

Philadelphia, PA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wistar scientists have developed a new tool that can help identify cancer-associated microbes by using machine learning technology.

Key Points: 
  • Philadelphia, PA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wistar scientists have developed a new tool that can help identify cancer-associated microbes by using machine learning technology.
  • Under the leadership of Dr. Noam Auslander — assistant professor in the Ellen and Ronald Caplan Cancer Center’s Molecular & Cellular Oncogenesis Program — the group has analyzed short read RNA-sequencing data to detect biomarkers for esophageal carcinoma, or ESCA.
  • Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status.
  • Wistar scientists are dedicated to solving some of the world’s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers.

Sonata Therapeutics Presents Data Supporting its Network Medicines™ Approach at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Survival, Mouse, Immunogenic cell death, ICD, Therapy, Society for Immunotherapy of Cancer, Cytokine, Lipid peroxidation, Sonata, MBA, Network medicine, SITC, San Diego Convention Center, Immunotherapy, Cell death, Cancer, Ferroptosis, Sarcoma, Chemokine, Annual general meeting, Messenger, Champalimaud Foundation, Society, Ground Level, Drug resistance, Synthetic biology, Pharmaceutical industry, Vaccine, Medical imaging

Sonata Therapeutics, Inc., a biotechnology company developing a new class of therapeutics called Network Medicines™, will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Sonata Therapeutics, Inc., a biotechnology company developing a new class of therapeutics called Network Medicines™, will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • In contrast, Sonata’s Network Medicines target pathways that change the complete dynamics of multifactorial diseases, resulting in more durable therapeutics and potentially better outcomes for patients.
  • Data demonstrate that ferroptosis induction is a promising strategy for the treatment of sarcomas, supporting Sonata’s continued investigation in syngeneic mouse models.
  • “Through our proprietary platform, Sonata is generating Network Medicines that move beyond the current immunotherapeutic paradigm.

Thought Leadership & Innovation Foundation (TLI) Sponsors TACA Autism Conference, Showcases Autism Knowledge Gateway

Retrieved on: 
Wednesday, November 1, 2023
Education, Other Health, Health, Philanthropy, Training, Research, Family, Foundation, Consumer, Science, Parenting, Knowledge, Developmental disability, Spectrum, Seizure, The Autism Community in Action, Chronic pain, Autism spectrum, MD, Face, Conference, Mentorship, FAAFP, Thiamine deficiency, TACA, Information Technology and Innovation Foundation, Ferroptosis, Gateway, Public, Puberty, ASD, TLI, GABA, Parent, Dietary supplement

“This remarkable event served as a lifeline for families touched by autism, providing them with direct access to renowned experts, The Autism Community in Action (TACA) mentors, sponsors, vendors and like-minded families from across the nation,” says Shawn Murphy, vice president, TLI.

Key Points: 
  • “This remarkable event served as a lifeline for families touched by autism, providing them with direct access to renowned experts, The Autism Community in Action (TACA) mentors, sponsors, vendors and like-minded families from across the nation,” says Shawn Murphy, vice president, TLI.
  • Additionally, TLI sponsored a think tank session which served as a hub of innovation where emerging research on seizures, intracellular ferroptosis, GABA and purine signaling networks, thiamine deficiency, chronic pain relief and the groundbreaking Autism Knowledge Gateway were showcased.
  • The Autism Knowledge Gateway is a dynamic resource in development.
  • A collaborative chat room within the Gateway facilitates in-depth discussions of case studies and current research among clinicians.

Sonata Therapeutics Announces Presentations Supporting its Network Medicines™ Approach at SITC 2023

Retrieved on: 
Monday, October 30, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Patient, Survival, Therapy, Society for Immunotherapy of Cancer, Network medicine, SITC, Immunotherapy, San Diego Convention Center, Ferroptosis, Abstract, Annual general meeting, Champalimaud Foundation, Society, Cancer, Drug resistance, Synthetic biology, Sarcoma, Pharmaceutical industry, Vaccine, Nightclub, Sonata

Sonata Therapeutics, Inc. , a biotechnology company developing a new class of therapeutics called Network Medicines™, today announced it will be presenting three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • Sonata Therapeutics, Inc. , a biotechnology company developing a new class of therapeutics called Network Medicines™, today announced it will be presenting three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • Network Medicines are drugs designed to modulate all the key cell types in networks of multifactorial diseases, thereby to halt or potentially reverse damage caused by such diseases.
  • In contrast, Sonata’s Network Medicines target pathways that change the complete dynamics of multifactorial diseases, resulting in more durable therapeutics and potentially better outcomes for patients.
  • One of the poster presentations will highlight one of Sonata’s Network Medicines, iART, that reprograms diseased cells to become the coordinators of cure for various indications including cancer.

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Retrieved on: 
Wednesday, August 9, 2023
HER3, Biotechnology, Knob, Ferroptosis, Conference, Pharmaceutical industry, Hillstream loach

Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and Minotaur Therapeutics, Inc.

Key Points: 
  • Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and Minotaur Therapeutics, Inc.
    BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced that it will be attending the Annual Sidoti Micro-Cap Virtual Conference being held on August 16-17, 2023.
  • “We’ve made a lot of progress since we’ve announced the strategic reprioritization of our drug pipeline making this an opportune time to share updates with the investment community,” says Randy Milby, CEO of Hillstream.
  • This will in turn complement Hillstream’s HSB-3215 program.
  • To schedule a meeting with the management team or view the presentation, please send an email to [email protected] or visit https://www.meetmax.com/sched/event_96493/investor_reg_new.html?attendee... .

The latest weapon against cancer is … a keto diet?

Retrieved on: 
Monday, June 12, 2023
Mouse, Cachexia, Neoplasm, Glucose, Weight loss, Cancer, Ferroptosis, Nutrient, Research, Hercules, Assistant, COLD, Death, Metabolism, Patient, CSHL, Divorce, Cold Spring Harbor Laboratory, Human, Fatigue, Disease, Dietary supplement, Pharmaceutical industry, Trapping

COLD SPRING HARBOR, N.Y., June 12, 2023 /PRNewswire/ -- Dietitians say a keto diet could help you lose up to 10% of your body weight. These high-fat, low-carb meal plans trick the body into burning its own fat. They could also help fight a variety of cancers by starving tumors of the glucose they need to grow. On the surface, this seems ideal. But research suggests these diets may have a deadly, unintended side effect for cancer patients.

Key Points: 
  • In mice with pancreatic and colorectal cancer , keto accelerates a lethal wasting disease called cachexia.
  • Janowitz and Ferrer are part of an international Cancer Grand Challenges effort taking on cancer cachexia .
  • The team is now working to fine-tune corticosteroid timing and dosage to widen the window for effective cancer therapies in combination with keto.
  • "If we can broaden this effect, make the treatment more efficient, we can ultimately benefit patients and improve cancer therapeutics.

Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders

Retrieved on: 
Monday, June 12, 2023
Neurology, Hospitals, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, Momentum, Communication, IPO, Partnership, Houston Methodist Hospital, Therapy, Result, Friends, Neurodegenerative disease, Food, Ferroptosis, Coronavirus Scientific Advisory Board, ALS, Hope, PET, Brain, Research, Melinda French Gates, Biomarker, Cerebrospinal fluid, Immunotherapy, Houston, Science, COYA, Thought, Bill & Melinda Gates Foundation, Oxidative stress, HIV disease progression rates, Patient, Coya, Blood, Frontotemporal dementia, Biology, Chemokine, POC, FDA, Letter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Positron emission tomography, Memory, News, Safety, Disease, Pharmaceutical industry, Medical imaging, Regulatory T cell

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman.
  • A Deeply Personal Mission: Like many of you, I lost a parent, my dad, to the debilitating effects of neurodegenerative disease.
  • As we assess our progress at mid-year, we believe our stockholders will be best served by laser focusing our financial resources and managerial energy on COYA 302 in ALS and COYA 301 in AD.
  • We will do everything within our power to drive safe, effective treatments for patients while creating long-term value for our stockholders.